The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It is
the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In …

The heterogeneity of hepatocellular carcinoma (HCC) commonly leads to therapeutic failure
of HCC. Cytokeratin 19 (CK19) is well acknowledged as a biliary/progenitor cell marker and …

Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in
terms of overall survival (OS) and a higher objective response rate (ORR) and better …

Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. To date,
most patients with HCC are diagnosed at an advanced tumor stage, excluding them from …

Purpose The purpose of this study is to compare response rates of lenvatinib and
atezolizumab plus bevacizumab, in first-line real-world setting. Methods Overall cohort …

Background Lenvatinib is a novel multiple receptor tyrosine kinase inhibitor used for
hepatocellular carcinoma (HCC) treatment. Although its main function is to suppress VEGFR …

Hepatocellular carcinoma (HCC) is a malignant type of primary liver cancer with high
incidence and mortality, worldwide. A major challenge in the treatment of HCC is …

Chlorogenic acid (CGA), a phenylpropanoid derived from Eucommia ulmoides Oliver, has
been shown to exhibit potent cytotoxic and anti-proliferative activities against several human …

Purpose This study aimed to investigate the efficiency of our chemically synthesized TT-
00420, a novel spectrum-selective multiple protein kinase inhibitor, in cultured cells and …